PharmaCyte Biotech Inc (PMCB)

[BioNewton]

You are not saying anything that everyone doesn't already know! Of course they can't market a treatment until it's approved no one is saying they can. People are merely pointing out what the orphan drug designation provides and that is seven years of marketing exclusivity in the US and 10 years of marketing exclusivity in Europe. With regard to the patents, you clearly don't know how patent protection works. A company doesn't extend its patents until one month prior to expiration.

Pharmacyte has a patent attorney already in place, so that likely means that they have a patent protection strategy in place. In case you were not aware, the CEO is an attorney and has worked with very large companies in the past so this isn't his first rodeo and the patent attorney that they're working with this is likely not his first rodeo. Some may hope that the company's patents will run out, but that is highly unlikely to happen because they are not just sitting around eating bonbons clueless as to how to protect their treatment and technology!!! You don't extend your patents until the last possible date obviously because you want as much time on the new patent as possible!